X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Biocon Ltd with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs TEVA PHARMA (Israel) - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 BIOCON LTD   TEVA PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
TEVA PHARMA
Dec-13
BIOCON LTD/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1622,839-   
Low Rs4832,466-   
Sales per share (Unadj.) Rs194.61,629.2-  
Earnings per share (Unadj.) Rs34.4101.8-  
Cash flow per share (Unadj.) Rs48.3233.5-  
Dividends per share (Unadj.) Rs1.0089.09-  
Dividend yield (eoy) %0.13.4 3.6%  
Book value per share (Unadj.) Rs241.91,809.7-  
Shares outstanding (eoy) m200.00848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.21.6 259.6%   
Avg P/E ratio x23.926.1 91.7%  
P/CF ratio (eoy) x17.011.4 149.9%  
Price / Book Value ratio x3.41.5 231.9%  
Dividend payout %2.987.5 3.3%   
Avg Mkt Cap Rs m164,4402,249,227 7.3%   
No. of employees `0009.244.9 20.5%   
Total wages/salary Rs m7,4700-   
Avg. sales/employee Rs Th4,213.930,738.8 13.7%   
Avg. wages/employee Rs Th809.00-   
Avg. net profit/employee Rs Th745.21,920.2 38.8%   
INCOME DATA
Net Sales Rs m38,9111,381,555 2.8%  
Other income Rs m1,5710-   
Total revenues Rs m40,4821,381,555 2.9%   
Gross profit Rs m9,795378,340 2.6%  
Depreciation Rs m2,772111,672 2.5%   
Interest Rs m26027,136 1.0%   
Profit before tax Rs m8,334239,531 3.5%   
Minority Interest Rs m1631,088 15.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-157,239 0.0%   
Tax Rs m1,616-2,924 -55.3%   
Profit after tax Rs m6,88186,305 8.0%  
Gross profit margin %25.227.4 91.9%  
Effective tax rate %19.4-1.2 -1,588.2%   
Net profit margin %17.76.2 283.1%  
BALANCE SHEET DATA
Current assets Rs m40,477933,097 4.3%   
Current liabilities Rs m16,783813,740 2.1%   
Net working cap to sales %60.98.6 704.8%  
Current ratio x2.41.1 210.3%  
Inventory Days Days6091 65.6%  
Debtors Days Days8396 86.4%  
Net fixed assets Rs m45,073451,246 10.0%   
Share capital Rs m1,0003,401 29.4%   
"Free" reserves Rs m47,3770-   
Net worth Rs m48,3771,534,646 3.2%   
Long term debt Rs m21,082706,420 3.0%   
Total assets Rs m93,9423,157,296 3.0%  
Interest coverage x33.19.8 336.4%   
Debt to equity ratio x0.40.5 94.7%  
Sales to assets ratio x0.40.4 94.7%   
Return on assets %7.63.6 211.6%  
Return on equity %14.25.6 252.9%  
Return on capital %12.64.9 255.7%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m5,0890-   
CASH FLOW
From Operations Rs m6,400220,148 2.9%  
From Investments Rs m-4,985-78,007 6.4%  
From Financial Activity Rs m-1,775-264,083 0.7%  
Net Cashflow Rs m-473-121,942 0.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 68.01 Rs / USD

Compare BIOCON LTD With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare BIOCON LTD With: DIVIS LABORATORIES  ALKEM LABORATORIES  TTK HEALTHCARE  CADILA HEALTHCARE  GSK PHARMA  



Today's Market

Indian Indices Trade in Red; US-China Trade War Back On; IPO Buzz and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened flat and ended the day in red. The S&P BSE Midcap Index ended down by 1% while S&P BSE Small Cap Index ended down by 1.3%.

Related Views On News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Jun 19, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - GSK PHARMA COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS